Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology • Medical Oncology • NCI-CCC Tumor Board Question • Yale • NCI-CCC Breast Tumor Board Question
When do you add an adjuvant bone-modifying agent in patients with history of localized breast cancer?
Is there any role for denosumab? How do you counsel patients regarding the benefit of bisphosphonates on breast cancer outcomes?
Answer from: Medical Oncologist at Academic Institution
Guidelines including ASCO/CCO, NCCN, St Gallen's, and ESMO all endorse the use of adjuvant bisphosphonates in early-stage breast cancer for postmenopausal women (natural or through suppression) at moderate to high risk of recurrence to reduce recurrence and fracture/BMD loss based on the patient lev...
Answer from: Medical Oncologist at Academic Institution
Dr. @Charles L. Shapiro and Dr. @Hatem H. Soliman both give reasonable answers. It appears at a first glance that postmenopausal women with osteoporosis risk receive most of the benefit from adjuvant bisphosphonate. I also give zoledronic acid q6m x 3-5 years in post-menopausal women at high en...
Comments
Medical Oncologist at Valley Med Onc
As an aside, I try to give the first dose of ZA wi...
As an aside, I try to give the first dose of ZA wi...
Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
There are several schedules of zoledronic acid rep...
There are several schedules of zoledronic acid rep...
Medical Oncologist at University of Pittsburgh School of Medicine
I tend to use ZA IV q6m. There are fewer side effe...
I tend to use ZA IV q6m. There are fewer side effe...
For lower risk patients (node-negative), do you ty...
I would consider any patient with a high FRAX and ...